Track Benitec Biopharma's long-term debt ($390K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), BNTC shows a long-term debt of $390K. That compares with $610K in the prior-year period — down 35.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BNTC's long-term debt is now $390K (was $610K) — a 35.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Benitec Biopharma is outperforming or lagging.
Tracking BNTC's long-term debt over time shows whether Benitec Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $390K That compares with $610K in the prior-year period — down 35.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Benitec Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $390K) with ownership activity and broader fundamentals.